EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nov. 18-21, 2014
Centre de Convencions Internacional Barcelona (CCIB)
Barcelona, Spain

Symposium Co-Chairpersons
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (EORTC)
Lee J. Helman, National Cancer Institute, Bethesda, Md., USA (NCI)
Jeffrey A. Engelman, Massachusetts General Hospital,
  Boston, Mass., USA (AACR)

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2014 Symposium will bring together over 2,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology. During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomised, multicenter cancer clinical trials. This requires a joint and global approach, and early and optimal exchange of information. For these reasons, the symposium has been organized to ensure the maximum amount of interaction and discussion through an exciting range of plenary sessions and lively workshops.

The symposium presents a unique opportunity to meet with academics and scientists in the field of drug discovery and targets in cancer all under one roof. Molecular Targets and Cancer Therapeutics 2014 will build on the success of the previous symposium which was widely praised for the quality of its program and inspirational contributions. This symposium will provide participants with additional educational opportunities as well as an excellent platform for networking. Make plans to join us at this unique platform in Barcelona and strengthen your links in the world of drug development, target selection, and molecular biology.